Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  2013-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/ATVBAHA.113.301282PMID 23559626PMCID PMC3717325
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys.

  2012cited by this paper
• ISIS-FXIRx, A Novel and Specific Antisense Inhibitor of Factor XI, Caused Significant Reduction in FXI Antigen and Activity and Increased aPTT without Causing Bleeding in Healthy Volunteers

  2011cited by this paper
• A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo.

  2010cited by this paper
• Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis

  2010cited by this paper
• Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.

  2010cited by this paper
• Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation

  2010cited by this paper
• RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

  2010cited by this paper
• Safety and Antithrombotic Efficacy of Moderate Platelet Count Reduction by Thrombopoietin Inhibition in Primates

  2010cited by this paper
• Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI.

  2009cited by this paper
• Reduced incidence of ischemic stroke in patients with severe factor XI deficiency.

  2008cited by this paper
• Article title: RELATIVE ANTITHROMBOTIC AND ANTIHEMOSTATIC EFFECTS OF PROTEIN C ACTIVATOR VERSUS LOW MOLECULAR WEIGHT HEPARIN IN PRIMATES

  2007cited by this paper
• Role of Factor XII in hemostasis and thrombosis: clinical implications

  2007cited by this paper
• The intrinsic pathway of coagulation: a target for treating thromboembolic disease?

  2007cited by this paper
• Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B

  2007cited by this paper
• Pharmacokinetic/Pharmacodynamic Properties ofPhosphorothioate 2'-O-(2-Methoxyethyl)-ModifiedAntisense Oligonucleotides in Animals and Man

  2007cited by this paper
• Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events.

  2006cited by this paper
• Effects of factor XI deficiency on ferric chloride‐induced vena cava thrombosis in mice

  2006cited by this paper
• Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII.

  2006cited by this paper
• Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery

  2006cited by this paper
• Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B

  2006cited by this paper
• Effects of factor IX or factor XI deficiency on ferric chloride‐induced carotid artery occlusion in mice

  2005cited by this paper
• [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].

  2004cited by this paper
• Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates.

  2003cited by this paper
• Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice.

  2002cited by this paper
• FXI Is Essential for Thrombus Formation Following FeCl3-Induced Injury of the Carotid Artery in the Mouse

  2002cited by this paper
• Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.

  2001cited by this paper
• High levels of coagulation factor XI as a risk factor for venous thrombosis.

  2000cited by this paper
• Risk Factors Associated with Postpartum Ovarian Vein Thrombosis

  1999cited by this paper
• Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.

  1996cited by this paper
• The coagulation cascade: initiation, maintenance, and regulation.

  1991cited by this paper
• Factor XI deficiency in Ashkenazi Jews in Israel.

  1991cited by this paper
• AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER

  1964cited by this paper
• An Enzyme Cascade in the Blood Clotting Mechanism, and its Function as a Biochemical Amplifier

  1964cited by this paper

• Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism

  2025cites this paper
• Factor XI inhibitors are the novel promising anticoagulants in the treatment of age related thrombotic disease

  2025cites this paper
• Safety of factor XI inhibitors compared to factor X inhibitors in atrial fibrillation: a systematic review and meta-analysis

  2025cites this paper
• The factor XIa antibody osocimab strongly inhibits clotting in extracorporeal circuits with human blood and in baboons

  2025cites this paper
• Emerging trends in anticoagulation therapy: a bibliometric analysis of DOACs and endogenous coagulation pathway inhibitors

  2025cites this paper
• Uncoupling Thrombosis and Hemostasis by Inhibiting Factor XI.

  2025cites this paper
• Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?

  2024cites this paper
• Dual Inhibition of Factor XIIa and Factor XIa Produces a Synergistic Anticoagulant Effect

  2024cites this paper
• Assessment and Management of Atrial Fibrillation in Older Adults with Frailty

  2024cites this paper
• Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome

  2024cites this paper
• New Targets for Antithrombotic Medications: Seeking to Decouple Thrombosis from Hemostasis.

  2024cites this paper
• Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings

  2024cites this paper
• Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XI

  2023cites this paper
• Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week.

  2023cites this paper
• Reversal agents for current and forthcoming direct oral anticoagulants.

  2023cites this paper
• Targeting Factor XI and Factor XIa to Prevent Thrombosis.

  2023cites this paper
• Reshaping Anticoagulation: Factor XI Inhibition in Thrombosis Management

  2023cites this paper
• Erratum to: The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology

  2023cites this paper
• Revised model of the tissue factor pathway of thrombin generation: Role of the feedback activation of FXI

  2022cites this paper
• Factor XI inhibitors: cardiovascular perspectives.

  2022influential citation
• Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients

  2022cites this paper
• Hemocompatibility of micropatterned biomaterial surfaces is dependent on topographical feature size

  2022cites this paper
• Coagulation factors XI and XII as possible targets for anticoagulant therapy.

  2022cites this paper
• Sulfonated non‐saccharide molecules and human factor XIa: Enzyme inhibition and computational studies

  2022cites this paper
• Factor XI as a target for preventing venous thromboembolism

  2022cites this paper
• Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism.

  2022cites this paper
• Factor XI, a potential target for anticoagulation therapy for venous thromboembolism

  2022cites this paper
• Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week.

  2021cites this paper
• First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa

  2021cites this paper
• Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition

  2021cites this paper
• Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe Anticoagulation.

  2021cites this paper
• Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target.

  2021cites this paper
• A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors

  2021cites this paper
• Evaluation of the Antihemostatic and Antithrombotic Effects of Lowering Coagulation Factor VII Levels in a Non-human Primate

  2020cites this paper
• Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates

  2020cites this paper
• Novel Antithrombotic Strategies for Treatment of Venous Thromboembolism.

  2020cites this paper
• Quantification of microbubble‐induced sonothrombolysis in an ex vivo non‐human primate model

  2020cites this paper
• Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia

  2020cites this paper
• Development of Coagulation Factor XII Antibodies for Inhibiting Vascular Device-Related Thrombosis

  2020cites this paper
• Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection

  2020cites this paper
• New anticoagulants: Moving beyond the direct oral anticoagulants

  2020cites this paper
• Turning Up to Eleven: Factor XI Inhibitors as Novel Agents to Maximize Safety and Maintain Efficacy in Thromboembolic Disease.

  2020cites this paper
• Studies on fragment-based design of allosteric inhibitors of human factor XIa.

  2020cites this paper
• Changes in Coagulation Parameters After Permanent Pacemaker Implantation

  2020cites this paper
• A novel rationale for targeting FXI: Insights from the hemostatic miRNA targetome for emerging anticoagulant strategies.

  2020cites this paper
• The rebirth of the contact pathway: a new therapeutic target.

  2020influential citation
• Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis

  2020cites this paper
• Factors IX, XI, and XII: potential therapeutic targets for anticoagulant therapy in atherothrombosis.

  2019cites this paper
• The contact system at the crossroads of various key patho- physiological functions: Update on present understanding, laboratory exploration and future perspectives.

  2019cites this paper
• BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics

  2019cites this paper
• Impact of Deficiency of Intrinsic Coagulation Factors XI and XII on Ex Vivo Thrombus Formation and Clot Lysis

  2019cites this paper
• From multi-target anticoagulants to DOACs, and intrinsic coagulation factor inhibitors.

  2019cites this paper
• Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass.

  2019cites this paper
• Allosteric Inhibition as a new mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated form of Coagulation Factor XI.

  2019cites this paper
• Potent, Orally Bioavailable and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.

  2019cites this paper
• Antithrombotic Agents: New Directions in Antithrombotic Therapy

  2019cites this paper
• Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation

  2019cites this paper
• Advances in Antithrombotic Therapy

  2019cites this paper
• MAA868 locks factor XIa in a zymogen-like state.

  2019cites this paper
• Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial

  2019cites this paper
• Intrinsic Pathway of Coagulation and Thrombosis: Insights From Animal Models

  2019cites this paper
• A novel rationale for targeting FXI: Insights from the hemostastic miRNA targetome for emerging anticoagulant strategies

  2018cites this paper
• New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds

  2018cites this paper
• Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.

  2018cites this paper
• Recent advances in the discovery and development of factor XI/XIa inhibitors

  2018cites this paper
• Factor XIa Inhibitors as New Anticoagulants.

  2018cites this paper
• Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency.

  2018cites this paper
• 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants

  2018cites this paper
• Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain

  2018cites this paper
• Factor XI promotes hemostasis in factor IX‐deficient mice

  2018cites this paper
• Plasma contact factors as therapeutic targets.

  2018cites this paper
• Current and emerging pharmacotherapy for ischemic stroke prevention in patients with atrial fibrillation

  2018cites this paper
• Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.

  2017cites this paper
• Fibrinogen and Fibrin in Hemostasis and Thrombosis.

  2017cites this paper
• The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials

  2017cites this paper
• Application of the Direct Oral Anticoagulants to Thromboprophylaxis of Mechanical Heart Valves

  2017cites this paper
• Advances in Anticoagulants

  2017cites this paper
• Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy

  2017cites this paper
• Monoklonale Antikörper und Antisense-Oligonukleotide – Biologika als Zukunft in der Kardiologie? // Monoclonal antibodies and antisense technology on the rise – The future of cardiovascular therapy?

  2017cites this paper
• Anti-thrombotic technologies for medical devices.

  2017cites this paper
• Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).

  2017cites this paper
• Factors XI and XII as Targets for New Anticoagulants

  2017cites this paper
• Emerging anticoagulant strategies.

  2017cites this paper
• Novel targets for anticoagulants lacking bleeding risk

  2017cites this paper
• Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis

  2017cites this paper
• New developments in anticoagulants: Past, present and future

  2017cites this paper
• Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes.

  2016cites this paper
• Management of Pulmonary Embolism: An Update.

  2016cites this paper
• Factor XI and factor XII as targets for new anticoagulants.

  2016cites this paper
• New Tools to Study Contact Activation

  2016cites this paper
• The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

  2016cites this paper
• Factor XIa inhibitors: A review of the patent literature

  2016cites this paper
• Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.

  2016cites this paper
• Medical device‐induced thrombosis: what causes it and how can we prevent it?

  2015cites this paper
• Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein.

  2015cites this paper
• Polyphosphate is a novel modulator of coagulation and inflammation and is a therapeutic target

  2015cites this paper
• Nowe perspektywy leczenia przeciwzakrzepowego — środki hamujące czynnik krzepnięcia XI

  2015cites this paper
• Pyridine and pyridinone-based factor XIa inhibitors.

  2015cites this paper
• Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway

  2015cites this paper
• Making (anti)sense of factor XI in thrombosis.

  2015cites this paper